Registered business in FR. Official registry identity, source coverage and the current valuation evidence status on one public company profile.
The latest filing has no usable positive EBITDA or the sector multiple is not available yet.
Create a free account to add verified turnover, normalised EBITDA, debt and one-offs for NOVARTIS PHARMA SAS in a private workspace.
We keep this public page conservative, so weak filings never become a false price.The page can still show filed facts, but the automatic public range is blocked when those facts would make the multiple misleading.
NOVARTIS PHARMA SAS is a business in NACE sector 46.46 based in France. The company was founded in 1996, incorporated as a 5710.
NOVARTIS PHARMA SAS is listed in French National Business Register (RNE/INPI) under registry number 410349070. The public employee band is 51, a useful triage field for banks, credit analysts, and M&A acquirers. This profile consolidates official annual accounts into one indexable company dossier.
Within the French NACE 46.46 cluster, public-record data is filed annually via the national company registry.
Across the 2016-2024 window revenue has grown, moving from €1,963,124,586 to €2,467,511,891.
The most recent annual filing covers 2024 (period end 2024-12-31).
If you are researching NOVARTIS PHARMA SAS for acquisition, investment, or due-diligence purposes, this page consolidates firmographics, filed accounts and the reason a public valuation curve is not shown yet.
NOVARTIS PHARMA SAS's public data is not clean enough for an automated valuation curve yet. Owner or advisor data can add the missing turnover, normalised EBITDA and adjustments.
Express interest and ask Upswitch to discreetly sound out the owner. We review every request before making contact.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Public regulator-filed figures across 8 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202431 Dec 2024 | €2,467,511,891 | - | €1,528,882,937 | €294,679,898 | - |
| 202331 Dec 2023 | €2,408,540,478 | - | €1,379,940,015 | €114,357,612 | - |
| 202231 Dec 2022 | €2,369,819,838 | - | €1,285,926,283 | €250,008,952 | - |
| 202131 Dec 2021 | €2,290,391,954 | - | €1,016,711,977 | €138,162,094 | - |
| 202031 Dec 2020 | €2,161,437,967 | - | €828,956,582 | €73,248,332 | - |
| 201931 Dec 2019 | €2,212,759,512 | - | €951,697,348 | €173,747,168 | - |
| 201731 Dec 2017 | €2,077,156,405 | - | €656,991,689 | €102,713,907 | - |
| 201631 Dec 2016 | €1,963,124,586 | - | €603,249,886 | €125,753,009 | - |
NOVARTIS PHARMA SAS was founded in 1996 and is registered with French National Business Register (RNE/INPI), incorporated as a 5710.
NOVARTIS PHARMA SAS is registered under NACE 46.46: NACE 46.46. That places the business within the French cluster for this activity.
The most recently filed annual accounts cover fiscal year 2024 (period end 2024-12-31), publicly available via French National Business Register (RNE/INPI).
This page shows official or licensed public company facts and valuation-readiness context for NOVARTIS PHARMA SAS; it does not show an automated public valuation range. The available facts may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
